CanSino Biologics Statistics

Total Valuation

CanSino Biologics has a market cap or net worth of HKD 10.66 billion. The enterprise value is 9.22 billion.

Market Cap	10.66B
Enterprise Value	9.22B

Important Dates

The next estimated earnings date is Monday, October 28, 2024.

Earnings Date	Oct 28, 2024
Ex-Dividend Date	n/a

Share Statistics

CanSino Biologics has 247.04 million shares outstanding. The number of shares has decreased by -0.38% in one year.

Shares Outstanding	247.04M
Shares Change (YoY)	-0.38%
Shares Change (QoQ)	+0.93%
Owned by Insiders (%)	42.03%
Owned by Institutions (%)	11.38%
Float	127.43M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	9.42
PB Ratio	1.19
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-9.90
EV / Sales	13.52
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-9.13

Financial Position

The company has a current ratio of 2.41, with a Debt / Equity ratio of 0.43.

Current Ratio	2.41
Quick Ratio	2.21
Debt / Equity	0.43
Debt / EBITDA	n/a
Debt / FCF	-2.34
Interest Coverage	-13.86

Financial Efficiency

Return on equity (ROE) is -16.60% and return on invested capital (ROIC) is -7.49%.

Return on Equity (ROE)	-16.60%
Return on Assets (ROA)	-6.49%
Return on Capital (ROIC)	-7.49%
Revenue Per Employee	593,458
Profits Per Employee	-810,480
Employee Count	1,494
Asset Turnover	0.07
Inventory Turnover	1.19

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +6.56% in the last 52 weeks. The beta is 0.52, so CanSino Biologics's price volatility has been lower than the market average.

Beta (5Y)	0.52
52-Week Price Change	+6.56%
50-Day Moving Average	20.74
200-Day Moving Average	19.54
Relative Strength Index (RSI)	55.47
Average Volume (20 Days)	1,870,484

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, CanSino Biologics had revenue of HKD 681.88 million and -931.24 million in losses. Loss per share was -3.77.

Revenue	681.88M
Gross Profit	159.46M
Operating Income	-1.01B
Pretax Income	-994.30M
Net Income	-931.24M
EBITDA	-784.77M
EBIT	-1.01B
Loss Per Share	-3.77

Full Income Statement

Balance Sheet

The company has 3.80 billion in cash and 2.36 billion in debt, giving a net cash position of 1.44 billion or 5.84 per share.

Cash & Cash Equivalents	3.80B
Total Debt	2.36B
Net Cash	1.44B
Net Cash Per Share	5.84
Equity (Book Value)	5.44B
Book Value Per Share	21.85
Working Capital	2.85B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -413.75 million and capital expenditures -596.22 million, giving a free cash flow of -1.01 billion.

Operating Cash Flow	-413.75M
Capital Expenditures	-596.22M
Free Cash Flow	-1.01B
FCF Per Share	-4.09

Full Cash Flow Statement

Margins

Gross margin is 23.39%, with operating and profit margins of -147.63% and -136.57%.

Gross Margin	23.39%
Operating Margin	-147.63%
Pretax Margin	-145.82%
Profit Margin	-136.57%
EBITDA Margin	-115.09%
EBIT Margin	-147.63%
FCF Margin	-148.12%

Dividends & Yields

CanSino Biologics does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.38%
Shareholder Yield	0.38%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

CanSino Biologics has an Altman Z-Score of 1.82. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.82
Piotroski F-Score	n/a